1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Atopic Dermatitis Financial Assistance Program is a patient assistance program from The Assistance Fund that provides financial support to individuals living with moderate-to-severe atopic dermatitis (eczema) who face difficulty affording prescription medications or treatment costs.
The program may cover co-pay assistance, free medication for uninsured patients, or other financial relief to help eligible patients access treatments such as biologics or topical therapies. Eligible applicants are typically patients with a confirmed diagnosis of atopic dermatitis who meet income thresholds and lack adequate prescription coverage. Patients should work with their dermatologist or healthcare provider to apply.
The program aims to reduce financial barriers and ensure patients with significant disease burden can access effective treatment regardless of their insurance status or economic situation.
Get alerted about grants like this
Save a search for “The Assistance Fund” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Cibinqo Savings Program 2026 | PrescriberPoint Assistance Fund: Atopic Dermatitis About The Assistance Fund: Atopic Dermatitis program offers essential support for patients prescribed drugs like Dupixent, Tacrolimus, and Rinvoq. By providing financial assistance for copays, coinsurance, and deductibles, this program ensures that eligible U.S. citizens or permanent residents receive FDA-approved treatments for atopic dermatitis.
With the Assistance Fund: Atopic Dermatitis, patients can access necessary medications and cover insurance premiums and medical expenses, all while benefiting from potential coverage of off-label drugs.
Insurance requirements : Commercially insured, Medicare / Medicaid Program Requirements • Valid only for residents in the US and Puerto Rico • Enrollment Required: Yes • Activation Required: No Program Details • Please note the following: • 1. Copay grant programs provide assistance for copays, coinsurance, and deductibles for FDAapproved treatment for the disease named in the disease program ONLY • 2.
Financial assistance grant programs provide assistance for other eligible outofpocket costs, such as health insurance premiums and incidental medical expenses, in addition to copay, coinsurance, and deductible assistance on FDAapproved treatment for the disease named in the disease program • 3.
This fund may cover offlabel drugs • Copay and Financial assistance can be utilized by any innetwork pharmacy or site of care able to dispense the medication or provide treatment • Program offers conditional approval of 30 days of immediate assistance for open programs where funding is available • Patients will be asked to provide and verify demographic, insurance, and financial information (additional documentation may be requested) • Approved patients will be granted assistance through the end of the calendar year unless otherwise specified for the applicable program
According to the current listing, eligibility includes: Eligible individuals living with atopic dermatitis. To learn more or determine eligibility for financial support, visit tafcares. org or call (833) 603-5297. Confirm the full requirements in the official notice before applying.
Atopic Dermatitis Financial Assistance Program is funded by The Assistance Fund. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
The Small Business Administration's Manufacturing in America Empower to Grow initiative funds up to ten technical-assistance organizations with $5M each to deliver hands-on training to small manufacturers in aerospace, shipbuilding, advanced manufacturing, and seven other priority sectors. Applications close June 15, 2026 — and the three-year continuous-operation requirement is the rule that ends most LOIs before they start.
Read articleFEMA has delayed $11 billion in Public Assistance reimbursements to 45 states while its Disaster Relief Fund nears depletion. What local governments and nonprofits need to do right now.
Read articleTABA adds up to $50,000 on top of your SBIR/STTR award for IP, market research, and regulatory help. Here is how to claim it before the money disappears.
Read article